Hero Mask
Hero Mask

NEWS

Discover how Chroma is expanding our impact.

PRESS RELEASES
Chroma Medicine Highlights Data Demonstrating Durable Multiplex Epigenetic Editing to Enhance Allogeneic CAR T at 65th ASH Annual Meeting
Boston, December 10, 2023 – Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today presented data demonstrating the potential of its multiplex epigenetic editing platform to enhance functional allogeneic chimeric antigen receptor (CAR) T cells at the American Society of Hematology (ASH) 65th Annual Meeting in San Diego. Allogeneic CAR T cell products offer advantages over autologous CAR T cells and have the potential to broaden access to cancer immunotherapy; however, their clinical effect remains limited by lack of durable response and challenges related to immunogenicity and graft-versus-host disease. Incorporating additional edits may help produce…
IN THE NEWS
Hepatitis B drug developers chart slow progress forward, just like hep C before it
PRESS RELEASES
Chroma Medicine Presents Preclinical In Vivo Data Showing Durable Cholesterol Reduction with a PCSK9-Targeted Epigenetic Editor at the 2023 AHA Scientific Sessions
Boston, November 11, 2023 – Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today presented new preclinical data demonstrating that a single administration of its epigenetic editor efficiently and durably lowered PCSK9 and cholesterol levels in non-human primates in a late-breaking oral presentation at the 2023 American Heart Association (AHA) Scientific Sessions, held November 11-13 in Philadelphia. The data presented provide strong evidence for the potential of Chroma’s epigenetic editing platform to silence expression of PCSK9 in the liver and to induce a durable reduction in low-density lipoprotein-cholesterol (LDL-C) levels, a key factor for reducing…
PRESS RELEASES
Chroma Medicine to Showcase Data Demonstrating Durable Multiplex Epigenetic Editing to Enhance Allogeneic CAR T at 65th ASH Annual Meeting
Boston, MA, November 2, 2023 – Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today announced that it will present a poster demonstrating the potential of its multiplex epigenetic editing platform at the American Society of Hematology (ASH) 65th Annual Meeting, taking place December 9-12, 2023, in San Diego, CA. The ASH abstract contains data showing the potential of multiplex epigenetic editing to produce functional allogeneic CAR T cells that do not exhibit a graft-versus-host-disease (GVHD) response, resist CD8+ and CD4+ T cell alloresponses, and resist the NK missing-self response normally consequent of reduced MHC…